Navigation Links
Newly-Published Study Concludes Stretta May Be More Desirable GERD Treatment than Chronic PPI Use or Anti-Reflux Surgery in Some Patients
Date:9/5/2013

GREENWICH, Conn., Sept. 5, 2013 /PRNewswire/ -- A newly published peer-review study that examines Stretta therapy is bringing renewed attention to this non-surgical procedure that has 10 years of patient data and recently earned The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) highest GRADE recommendation.

(Photo:  http://photos.prnewswire.com/prnh/20130211/NY56794 )

The study, published in Gastroenterology Research and Practice, is titled "Stretta Radiofrequency Treatment for GERD: A Safe and Effective Modality" and presents facts that dispel some misconceptions about Stretta. The study concludes that Stretta is a safe and effective treatment in patients for whom PPI therapy is undesirable, or the many that prefer less invasive treatment options.

Authored by Drs. Mark Franciosa and Hiroshi Mashimo, of the Center for Swallowing and Motility Disorders in Boston, VA Boston Healthcare System and Harvard Medical School, and Dr. George Triadafilopoulos of the Division of Gastroenterology and Hepatology in Stanford University School of Medicine, the study cites experimental and clinical data from a multitude of sources and concludes that Stretta is a valuable non-surgical treatment option in the management of GERD.

Stretta uses low power and low temperature radiofrequency (RF) energy to remodel the lower esophageal sphincter muscle, thus reducing Gastroesophageal Reflux Disease (GERD) and its symptoms.

"This review of the abundant clinical data, including controlled and randomized studies, as well as studies with long-term follow up, concludes that Stretta is safe, effective and long-lasting – and a valuable option for many patients seeking relief from their GERD symptoms," stated Dr. Triadafilopoulos. "This is particularly important in light of current concern about long-term PPI use and patient resistance to anti-reflux surgery," stated Dr. Triadafilopoulos.

With the NIH reporting that approximately 20 percent of Americans suffer GERD symptoms at least once a week, doctors are seeking treatment options for GERD.  SAGES recently published clinical guidelines (August '13 Surgical Endoscopy) that gave Stretta therapy a GRADE recommendation of "++++/strong," citing high quality evidence from 32 clinical trials. Recently presented 10-year post-Stretta data concluded that Stretta is an effective long-term solution for GERD patients.

Dr. Triadafilopoulos pointed to data presented in the study showing Stretta has the longest experience of any non-surgical intervention. "As doctors, we strive to improve the quality of life of patients," Triadafilopoulos stated. "We owe it to GERD sufferers to offer this valuable treatment option."

For more information on Stretta go to stretta-therapy.com.

ABOUT STRETTA®

Stretta is a minimally invasive treatment for GERD that is an effective option for patients who do not respond well to medications. Stretta involves delivery of RF to the LES and gastric cardia. Studies show Stretta is a safe, effective and durable therapeutic option. Stretta does not preclude further steps with more invasive procedures if indicated. Stretta is currently covered by many insurance plans.

ABOUT MEDERI®

Mederi Therapeutics manufactures and markets innovative medical devices that deliver RF energy to treat diseases of the digestive system. Mederi therapies are outpatient, minimally invasive and promote rapid recovery.

Contact: Julia Brannan
(908) 464-2470
julia@pascalecommunications.com


'/>"/>
SOURCE Mederi Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Adynxx Completes Patient Enrollment in Phase 2 Clinical Study of Lead Therapeutic for Prevention of Pain, AYX1
2. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
3. SERVE-HF; the Worlds Largest Study of Sleep-Disordered Breathing in Heart Failure Completes Recruitment
4. Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ATOMIC-AHF Study Of Omecamtiv Mecarbil
5. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
6. St. Jude Childrens Research Hospital study yields new strategy against high-risk leukemia
7. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
8. Ruggles Family Foundation and Mr. and Mrs. Rudy L. Ruggles, Jr. Make $1.25M Donation to J. Craig Venter Institute for New Study to Identify and Elucidate Healthy Aging Biomarkers
9. Study Demonstrates Glysure Systems Ability to Accurately Measure Blood Glucose Levels in the ICU
10. Rigels R343 Did Not Meet Primary Endpoint in Asthma Study
11. New Study Explores Medical Affairs Capabilities in Mature and High-Growth Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)...  Interpace Diagnostics Group, Inc. (NASDAQ: IDXG), a fully ... tests and pathology services, announced today the acceptance of ... United States and Canadian Academy of ... San Antonio, Texas . ... the Company,s extensive experience in molecular thyroid testing, including ...
(Date:2/27/2017)... CAESAREA , Israel and TAMPA, Fla. ... Heart Ltd., an emerging medical device company focused ... undergoing cardiac procedures, applauds the members of the ... past week for their acknowledgement of the need ... (TAVR) surgery. "The statements shared by ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology:
(Date:2/27/2017)... ... ... The threat of nuclear warfare has long plagued this world. In July ... testing of nuclear weapons. Years later, when her co-workers began dying, Dot started searching ... Testing,” Clayton exposes the critical decisions made by agencies involved in the nuclear testing ...
(Date:2/27/2017)... , ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. ... has disclosed that despite scientific studies, the Center for Disease Control ( CDC ) ... disease . Kenneth B. Liegner, M.D. has compiled into a single volume a ...
(Date:2/27/2017)... ... 2017 , ... New Jersey ranks among the top five states in the ... need for advanced services is growing. , Project WE vs C is a ... with their non-profit partners in their fight against cancer and in support of their ...
(Date:2/26/2017)... York, New York (PRWEB) , ... February 26, ... ... luxury baby products for wholesale distribution in North America, today announced it would ... online sites. The company, which prides itself on crafting quality and unique baby ...
(Date:2/26/2017)... ... February 26, 2017 , ... Occupational pesticide exposure is linked ... LRRK2 mutation, according to a study released today at the 1st Pan American ... link between pesticides and incidence of sporadic PD through occupational exposure. This latest ...
Breaking Medicine News(10 mins):